Overview
- Anne Wojcicki’s nonprofit TTAM Research Institute submitted a $305 million bid to acquire substantially all of 23andMe’s assets, surpassing Regeneron Pharmaceuticals’ earlier $256 million offer.
- A hearing on June 17 in the U.S. Bankruptcy Court for the Eastern District of Missouri will determine whether the deal moves forward.
- Twenty-eight state attorneys general led by New York’s Letitia James filed suit to block the sale of customers’ genetic data without explicit consent.
- TTAM Research Institute pledged to honor 23andMe’s privacy policies, let customers delete their data or opt out of research and form a Consumer Privacy Advisory Board within 90 days of closing.
- Since 23andMe’s Chapter 11 filing in March, about 1.9 million customers—around 15 percent—have requested deletion of their genetic information.